LISAvienna e-Newsletter 03/2014
View this email in your browser
Dear Readers, 

Vienna is one of the most active life science locations in Europe. To further strengthen biotech, pharma and medtech, the Vienna Business Agency is putting a special focus on life sciences until the end of this year. Centerpiece is a new call for R&D projects. Its start will be celebrated next Tuesday, June 17, at our Life Science Circle. Find all details including special conditions at additional funding schemes here

Extended deadline for registration: Join the WKO Delegation Trip to Israel, September 21-24, 2014!
Register until June 30 and establish successful initial business contacts with biotech, pharma and medtech companies and the Venture Capital landscape based in Israel.  » Info & Registration
Jürgen Fuchs  will be happy to provide you with further details.
BioEquity Europe 2015 in Vienna: We are delighted that we have been successful in attracting the most important investor conference for biotech in Europe to Vienna. >> Click here for further details!
New event reports and photos online: LISAvienna recently participated in EuroMedtech, conhIT  and a business delegation trip to China and Japan. Learn more about these events and the Business Seminar on Israel.
We look forward to meeting you at one of the upcoming events in Vienna or at BIO in San Diego.
Enjoy reading!

FUNDING Opportunities  in Vienna  

NEW at aws: international biotech & medtech business plan competition 
Develop your business idea and benefit from 1-on-1 coaching now! Cash prizes totaling 44,500 Euros, sponsored by Roche, Binder Grösswang, ARGE LISAvienna and AFFiRiS await the best ideas and business plans. Deadline for the submission of business ideas is September 15

aws: PreSeed and Seedfinancing
aws offers up to 200,000 Euros PreSeed money for foundation projects to prepare proof of principle or proof of concept. For high-tech start-ups Seedfinancing is available: a conditionally repayable subsidy of up to 1 Million Euros combined with consultation and support. 

Vienna-based biotech, pharma and medtech companies have the chance to receive significant funding for their R&D efforts. Overall, 2 Million Euros for innovative projects are available now!
Submit your project proposal by September 17.
Vienna Business Agency: Location Initiative
Companies that set-up or relocate to or within Vienna or that significantly extend their premises in the city can apply for monetary funding. Up to 500,000 Euros for SMEs and 200,000 Euros for large enterprises are available. Deadline for the submission of (re)location plans is June 30.

Further funding schemes to explore:
FFG Clinical Studies: SME-driven phase I or II studies conducted together with at least one hospital in Austria.
FFG Orphan Diseases: R&D for diagnosis, therapy and medication focusing on rare diseases.
Deadlines to remember:
July 23: End of submission period for grant applications at OeNB's Anniversary Fund
July 24: Vienna Research Group Call 2014 at WWTF closes
August 15: Deadline for submitting proposals for CD Labs and JR Centers at CDG
September 4: BRIDGE 1 Call (nanotechnology/converging technologies) closes at FFG
October 17: Deadline for the new Innovative Services Call focusing on Start-ups at aws 
Visit for a comprehensive update
on the hottest news from the Life Science City Vienna!

Themis Bioscience: Threat of emerging virus can be stopped

June 12, 2014 – A prophylactic vaccine candidate against Chikungunya fever, developed by the Austrian biotech company Themis Bioscience GmbH induces a significant neutralizing immune response and was also confirmed as safe. These are the major interim results of a phase 1 clinical study of the company's Chikungunya vaccine candidate that uses a standard anti-measles vaccine as a vector.  Â» read more

Eucodis Bioscience: INVISTA collaboration on development of enzymes for the production of industrial chemicals

June 5, 2014 - INVISTA and Eucodis Bioscience, an Austrian biotechnology company with strong expertise in enzyme engineering and industrial enzyme development, announce a collaboration for the screening and engineering of enzymes to further develop bio-derived processes for the production of industrial chemicals. » read more 

AFFiRiS: breakthrough In Alzheimer's Disease

June 4, 2014 - AFFiRiS announced the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
 Â» read more
Recently, AFFiRiS also announced to lead a European Consortium that has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). » read more

IMP: novel method to study the activity of specific brain regions in moving flies 

May 25, 2014 - In a joint effort with collaborative partners from the Vienna University of Technology and a lab in the USA, IMP researchers developed a special device for the thermogenetic control of flies. This tool enabled scientists to target light or heat to specific body regions of flies in motion and to analyze the insects‘ brain cells. The results have been published in Nature Methods. » read more 

Miracor Medical Systems  to release latest clinical data about its PICSO Impulse System

May 14, 2014 - Miracor has begun European commercialization of the CE-marked PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) system as an adjunct to angioplasty in acute STEMI patients. Clinical data involving a study of its PICSO® have been presented at “EuroPCR”.
» read more 
Furthermore, Miracor met VCs in Ireland recently. » read more

Boehringer Ingelheim will make detailed clinical trial data available to the scientific community

May 13, 2014 -  In order to add to scientific and medical progress, Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug development program. » read more 
Besides, Boehringer Ingelheim Regional Center Vienna announced that new drugs secure company growth in the region. BI's Vienna site is currently being extended. Â» read more 

Nabriva Therapeutics  presented extended spectrum pleuromutilin antibiotics in Barcelona

May 12, 2014 - Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for treatment of serious infections caused by resistant pathogens, announced that four posters will be presented on the Extended Spectrum Pleuromutilins (ESP) Program at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2014) in Barcelona. Â» read more

Platynereis functional advancements as one of Genetics’ May highlights

May 9, 2014 - Researchers at the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna made a breakthrough for the Platynereis model system, as they describe the first method for generating specific and inheritable mutations in the species. The study and a review on Platynereis dumerilii genetic methods were chosen by the renowned journal Genetics as one of the May 2014 Highlights and also got the cover image. Â» read more 

Vetmeduni Vienna: new cause of high blood pressure and heart disease discovered

May 5, 2014 - Why phosphate rich foods can increase blood pressure and promote vascular calcifications has been discovered by scientists at the Vetmeduni Vienna. The key is the hormone, FGF23 (Fibroblast Growth Factor 23). When the level of FGF23 is raised, as through a high phosphate diet, calcium and sodium accumulate. The study has been published in the journal EMBO Molecular Medicine. » read more 

MedUni Wien:  new combination therapy for hepatitis C and new method of diagnosis of depression

May 5, 2014 - A new combination therapy allows chronic hepatitis C to be treated in a manner that is less aggressive yet equally efficient. This breakthrough has been published in the New England Journal of Medicine. » read more 
Recently, researchers at MedUni Wien also found out that a blood-based test for depression is a realistic option.
» read more 

TU Wien:  less time at the dentist with new photoactive molecules 

April 28, 2014 – A newly developed dental filling material allows light to penetrate deeper and can therefore be cured in less steps than previously. A Germanium-based photo initiator enables this. » read more 


TissueGnostics: announces a significant expansion in Asia

April 27, 2014 - In close collaboration with its Chinese distributor TissueGnostics GmbH, Vienna, has established its China Division. It is a joint endeavor between TissueGnostics and Beijing Huawei Zhongyi Technology. Having a direct presence of the brand “TissueGnostics” in China better meets the expectations of customers in this Asian marketplace. Â» read more 

IMBA:  cover story in “CELL”, new neurological syndrome in children discovered 

April 25, 2014 - An international team including researchers from the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences has found a new neurodegenerative syndrome in children that coincides with disorders of the brain and peripheral nervous system.
» read more 
Recently, research results at IMBA also opened up perspectives for new treatment strategies for numerous types of breast cancer and leukemia. » read more 

 VAMED  further expands its international market presence 

April 24, 2014 - With almost 16,000 employees worldwide, the healthcare group VAMED expanded its international market presence even further and entered nine new markets last year. The sales target of 1 billion euro was achieved one year earlier than planned. VAMED currently serves 380 health facilities with more than 110,000 beds. » read more 

Hookipa  receives additional grant support from FFG for development of vaccine candidate HB101

April 22, 2014 - Hookipa Biotech AG, a biotech company pioneering a new class of vaccines, today announced the award of a major grant from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft, FFG), the leading public funding agency for translational research in Austria. » read more 
Your news placed here: Vienna-based organizations are invited to e-mail news and press releases to to contribute to LISAvienna's digital and print media.
Upcoming EVENTS in Vienna  
  • BOKU: opening ceremony bioindustrial plant and launch of Simon Zeisel building 
    June 17, 2014 – 3 p.m.
    Armin Szilvinyi building, ground floor, lecture hall XX, Muthgasse 18, 1190 Vienna
    BOKU's new bioindustrial core facility is finished. This will be celebrated together with the new name for Muthgasse 3 which will become the Simon Zeisel building. A summer party organized by the university's students will complete the event

  • 1st European Pneumo Update
    June 20-21, 2014
    Aula der Wissenschaften, Wollzeile 27a, 1010 Vienna
    The most relevant clinical pneumology papers of the last year will be reviewed and put into perspective, and today’s burning issues will be addressed. The European Pneumo Update was granted 11 European CME credits by the EACCME. 

  • 5th Meeting of the European Society for Evolutionary Developmental Biology - EuroEvoDevo
    July 22-25, 2014
    Campus of the University of Vienna, Spitalgasse 2-4, Court 2, 1090 Vienna
    Some 500 participants are expected to convene at EuroEvoDevo 2014. The scientific program consists of plenary sessions, symposia, contributed talks and poster sessions by scientists from all over the world. 
Copyright © LISAvienna 2014, All rights reserved.
Foto Intro © Tech Gate Vienna, Foto: Clemens Horvath

Our mailing address is:

unsubscribe from this list    update subscription preferences 

LISAvienna is a joint initiative of Austria Wirtschaftsservice and the Vienna Business Agency to foster life sciences in Vienna. The Austrian Federal Ministry of Science, Research and Economics and the City of Vienna join forces to ensure that the economic potential of the life sciences is put to good use and turned into marketable products, improved processes and new services.